Business
Telo Genomics Announces the Outcome of its Participation in the International Myeloma Workshop and Clinical Studies Progress
Toronto, Ontario--(Newsfile Corp. - October 13, 2021) - Telo Genomics Corp. (TSXV: TELO) (th...
About this update from Telo Genomics Corp.
[{"type":"text","content":"Telo Genomics Announces the Outcome of its Participation in the International Myeloma Workshop and Clinical Studies ProgressToronto, Ontario--(Newsfile Corp. - October 13, 2021) - Telo Genomics Corp. (TSXV: TELO) (the \"Company\" or \"TELO\") is pleased to announce updates related to its recent participation in the International Multiple Myeloma Workshop in Vienna, Austria, and progress of the ongoing clinical studies in collaboration with the Mayo Clinic. TELO has recently participated in the International Myeloma Workshop (IMW 2021) that took place in Vienna, Austria. During the IMW 2021 TELO held important meetings with influential Lead Investigators of multiple myeloma Clinician groups from the USA, France, Spain and Portugal. These meetings were highly productive focused on the development of new collaborations to advance the clinical studies that the Company is currently conducting and in turn accelerate the commercialization of the Company's prognostic tests in-development. TELO also advanced the discussions with potential collaborators addressing additional specific clinical unmet needs in the management of multiple myeloma.The International Myeloma Society (IMS) is a professional, scientific, and medical society established to bring together clinical and experimental scientists involved in the study of myeloma. IMS promotes the advancement in multiple myeloma disease management through its International Myeloma Workshop (IMW). The IMW is held on an annual basis and includes the meetings of the myeloma guidelines committees. These committees develop, review and revise the guidelines used internationally for multiple myeloma diagnostics and treatments.The Company also announces that it has successfully completed the processing of the first batch of myeloma samples, which was received from the Mayo Clinic earlier in the year. This batch of patient samples represents the overall feasibility assessment of the ongoing clinical studies included in TELO's collaboration with the Mayo Clinic. During the IMW 2021 TELO held an important meeting with the study's Lead Clinical Investigator from the Mayo Clinic to discuss the results of the Feasibility Assessment samples. TELO is expecting to receive the following batch of samples from the Mayo Clinic within Q4 of the current year. TELO's collaboration with the Mayo Clinic includes tw...